Ultragenyx Made $201 Million Of Gene Therapy Before Approval, And Its Books Show Zero
Two newly approved gene therapies will ship from stock expensed earlier, so early sales carry little cost and margins should fall later.
Ultragenyx Pharmaceutical, which develops treatments for rare and ultra-rare genetic diseases, made gene therapy batches before approval that cost roughly $113 million for GENGLYCOS and $88 million for FAYUVI, its 10-Q filed Wednesday estimates. The balance sheet assigns that inventory nothing, since the spending was booked as research and development.
Free inventory, then full cost
The company expenses manufacturing costs before regulatory approval and capitalizes them only for batches started after it. Approvals came in August 2026 for GENGLYCOS and September 2026 for FAYUVI, so earlier batches will leave cost of sales untouched when sold.
There were no sales of either product in the quarter, so cost of sales has not yet been affected. The old stock should last until late 2027 for FAYUVI and late 2028 for GENGLYCOS. It then expects its gross margin percentage to fall as it sells product carrying full manufacturing cost.
Because overhead was never assigned to individual pre-approval runs, the company backed into the cost figures using overhead from a typical stretch of steady production.
Patient weight sets the timetable
Dosing by body weight means vials per patient vary materially. The 10-Q says cost of sales as a share of revenue will swing with the weight profile of patients treated, even after the old stock is gone.
Heavier patients could exhaust the inventory sooner and bring higher costs earlier, the risk factors say. Lighter patients could leave stock to expire and require write-offs. Compassionate-use and patient-access programs draw on the same supply.
The prior quarterly filing, filed in August, did not carry this inventory discussion. The new 10-Q flags the inventory change in its critical accounting estimates.
Cuts, vouchers and a 2027 profit target
Ultragenyx reported third-quarter revenue of $173 million and a net loss of $118 million, against a $180 million loss a year earlier. It held $401 million in cash and securities at September 30.
The company is cutting about 20% of its workforce after its Angelman syndrome study failed to hit its main goal and it ended the UX701 Wilson disease program. It still targets profitability in 2027. Its risk factors warn that much of 2027 product revenue is expected to come from named patient sales of the two gene therapies in markets lacking approval or reimbursement.
The company sold the voucher from the GENGLYCOS approval on October 30 for $210 million. The FAYUVI voucher sale, at $203 million, is expected to close by year end 2026, and the company expects combined net proceeds of $349 million.
The first reported GENGLYCOS and FAYUVI sales will show how much the expensed inventory flatters early margins.
Sources
- 10-Q Filing — Ultragenyx Pharmaceutical (RARE) — SEC EDGAR
- 10-Q Filing — Ultragenyx Pharmaceutical (RARE), Q2 FY2026 filed 2026-08-05 (comparison basis) — SEC EDGAR
- 8-K Filing — Ultragenyx Pharmaceutical, filed 2026-11-03 (Items 2.01, 2.02, 2.05, 9.01) — SEC EDGAR
- Earnings release (8-K Item 2.02, rare-ex99_1.htm) — Ultragenyx Pharmaceutical, filed 2026-11-03 — SEC EDGAR
